NEW YORK, July 7, 2011—Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, has appointed Dr. Oria Madi as Post-Approval and Non-Interventional Studies Director. Dr. Madi will be in charge of growing Kantar Health France’s expertise in non-interventional and pharmacoepidemiological studies and will work closely with Dr. Michel Murino, CEO of Kantar Health France.
A specialist in rheumatology, Dr. Madi worked as a private practitioner before joining the pharmaceutical industry. She has held different positions at Procter & Gamble, Pfizer, Sanofi and GSK. During her career, she has had the opportunity to launch a number of molecules and to develop her expertise in post-approval and non-interventional studies. After earning a Business Consulting degree at ESCP, Dr. Madi started a consultancy for the pharmaceutical industry, which she developed over the next five years.
About Kantar Health France
Kantar Health France supports the strategic and operational decisions of its customers within the pharmaceutical industry, committees of experts, learned societies, healthcare facilities, institutions and patient organizations. We conduct more than 500 studies per year, many of them published in scientific journals.